Nuvation Bio reported Q3 revenue of $45.0M and received an FDA label update for IBTROZI's median duration of response, signaling continued dominance in the ROS1 NSCLC market.
Nuvation Bio reported Q3 revenue of $45.0M and received an FDA label update for IBTROZI's median duration of response, signaling continued dominance in the ROS1 NSCLC market.